Tests conducted in Brazil with the vaccine under development by the University of Oxford and AstraZeneca against Covid-19 have so far not reported serious adverse events in volunteers, according to the National Health Surveillance Agency.
The information, released by the agency on Wednesday (9), comes a day after AstraZeneca announced a temporary suspension of testing with the vaccine due to the suspicion of a serious adverse reaction in a UK participant.
Anvisa says it has received a statement from AstraZeneca about the temporary suspension of testing of the ChAdOx1 nCoV-19 vaccine and that it is monitoring the case.
The company decided to temporarily stop tests and investigate the event. There is still no confirmation that the case is related to the vaccine, which should be evaluated.
Still, in a note, Anvisa informs that it is in contact with the laboratory "for access to all the information and for dialogue with other medicine authorities in the world."
The objective is to verify if the unexpected effect is related to the vaccine applied. The investigation takes place through an independent safety committee, composed of international researchers not linked to the study.
"This type of procedure is foreseen in the development of vaccines since these studies have precisely the objective of confirming the safety and effectiveness of vaccines," adds Anvisa.
"In Brazil, there are no reports of serious adverse events in volunteers," the agency said.
Translated by Kiratiana Freelon